(Sept 6, 2008)
Just a distant possibility at this point but it's something entering trials that may have a dry eye application later on depending on Phase I results.
SOUTH SAN FRANCISCO, Calif., September 05, 2008 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases. Sunesis and SARcode entered into a license agreement providing SARcode with an exclusive license to Sunesis' LFA-1 technology to develop LFA-1 inhibitors in March 2006.
"LFA-1 antagonists mediate both migration and adhesion of the white blood cells to sites of inflammation as part of the body's immune response," said Tom Gadek, Ph.D., chief executive officer of SARcode Corporation. "Lead indications for LFA-1 include dry eye and allergic conjunctivitis, both large indications with unmet medical needs. The results of this study will inform dose selection for several Phase 2 studies to commence in the first half of 2009."
No comments:
Post a Comment